Lorrain Daniel S.'s Form 4 filing
Contineum Therapeutics, Inc. (CTNM) · filed Feb 26, 2026
- Accession no.
- 0001437749-26-005889
- Filed
- Feb 26, 2026
- Trade date
- Feb 24-25, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $130.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lorrain Daniel S.CIK 0001861550 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | Class A Common Stock | MOption exerciseAcquired | +4,300 | $1.01 | +$4,343 | 160,352 | Direct | |
| Feb 24, 2026 | Class A Common Stock | SSaleDisposed | −4,300 | $16.03 | −$68,929 | 156,052 | Direct | |
| Feb 25, 2026 | Class A Common Stock | MOption exerciseAcquired | +3,824 | $1.01 | +$3,862.24 | 159,876 | Direct | |
| Feb 25, 2026 | Class A Common Stock | SSaleDisposed | −3,824 | $16.01 | −$61,222.24 | 156,052 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | Class A Common Stock | MOption exerciseDisposed | −4,300 | $0.00 | $0 | 71,130 | Direct | |
| Feb 25, 2026 | Class A Common Stock | MOption exerciseDisposed | −3,824 | $0.00 | $0 | 67,306 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.